Home > Latest News on ID > Infectious Disease News
[News released on Apr 8, 2009]Phase I Clinical Trial for a New Streptococcus Pneumoniae Vaccine
Date: 2009-04-09   Read: 100281

Intercell Starts a Phase I Clinical Trial for a New Streptococcus Pneumoniae Vaccine

Intercell AG (VSE: ICLL) announced that a Phase I clinical trial with the company's vaccine candidate IC47 to prevent disease caused by the bacterium Streptococcus pneumoniae has started.

Intercell's vaccine candidate is a recombinant subunit vaccine consisting of three conserved surface proteins from S. pneumoniae. Two of these proteins were discovered using Intercell's proprietary Antigen Identification Program (AIP(R)), while the third was in-licensed from the U.S. Centers of Disease Control and Prevention (CDC).

This Phase I trial is a first-in-man study with a focus to obtain safety and immunogenicity data in a small population of healthy adults. Thirty-two subjects will be enrolled in this open-label study. Two different vaccine concentrations either with or without the addition of an adjuvant will be tested.

"The initiation of this clinical Phase I trial is an important step to further strengthen Intercell's leading position in the development of vaccines against infectious diseases with significant unmet medical need," commented Intercell's Chief Scientific Officer, Alexander von Gabain.

Although vaccines against S. pneumoniae are available, they cover only a restricted number of the more than 90 known serotypes and it is essential to pursue new vaccines for distribution in countries with the highest medical need for an effective vaccine against the pathogen. Intercell's novel vaccine candidate is composed of highly conserved proteins of S. pneumoniae that have the potential to protect against all serotypes.

The development of Intercell's vaccine to prevent pneumococcal disease is supported by PATH - a U.S.-based non-profit organization that creates sustainable, culturally relevant solutions that enable communities worldwide to break longstanding cycles of poor health. Having supported the preclinical studies of the IC47 vaccine, PATH has now committed another USD 3.6 m for the further clinical development until Q2 2010, including the Phase I trial. Under the terms of the collaboration, Intercell will develop the vaccine and make it available at an affordable cost for children in developing world countries at greatest need, where Pneumococcus is a major cause of infant and childhood mortality.


Adapted from materials provided by Medical News TODAY

Next [News released on Apr 9, 2009]Multidrug-resistant gram-negative bacteria high in long-term care 2009-04-28 99339
Previous [News released on Mar 19, 2009] Extensive patient sharing among hospitals; could impact spread of infectious diseases 2009-04-09 100311
޴ٷΰ ΰ